Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
Panacea Innovation Ltd - 30 Jan 2025 SCHEDULE 13G Report for Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA)
- Filing manager
- Panacea Innovation Ltd
- Reporting owner
- Panacea Venture Healthcare Fund II, L.P.
- Beneficially owned shares
- 550,000 shares
- Large-stake signal
-
Ownership
9.5%Beneficial ownership of this reported class.
Shares
550,000 sharesShares beneficially owned as disclosed.
Event date
30 Jan 2025Date tied to the ownership event or amendment.
Accepted by SEC
06 Feb 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 9.5%
- Symbol
- ATRA
- Shares outstanding
- 5,789,474 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 06 Feb 2025, 18:34:13 UTC
- Event date
- 30 Jan 2025
- Next SEC filing
- 11 May 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Panacea Innovation Ltd disclosed 9.5% ownership in Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA) on 30 Jan 2025.
Key facts
- Panacea Innovation Ltd filed SCHEDULE 13G for Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (ATRA).
- Disclosed ownership: 9.5%.
- Date of event: 30 Jan 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 06 Feb 2025, 18:34.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (4)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Panacea Venture Healthcare Fund II, L.P. | 9.5% | 550,000 | 0 | 550,000 | By: Panacea Venture Healthcare Fund II GP Company, Ltd., its general partner, By: Panacea Innovation Limited, its sole owner, /s/ James Huang | James Huang, Founding Managing Partner | |
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 9.5% | 550,000 | 0 | 550,000 | By: Panacea Innovation Limited, its sole owner, /s/ James Huang | James Huang, Founding Managing Partner | |
| Panacea Innovation Limited | 9.5% | 550,000 | 0 | 550,000 | /s/ James Huang | James Huang, Founding Managing Partner | |
| James Huang | 9.5% | 550,000 | 0 | 550,000 | /s/ James Huang | James Huang |
CIK / CUSIP context first